Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms

Xu,Qian; Wang,Ji; Chen,Feifei; Lin,Kaisu; Zhu,Mingao; Chen,Lei; Zhou,Xiumin; Li,Chong; Zhu,Hong

doi:10.3892/ijmm.2016.2603

Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms

Authors:
- Qian Xu
- Ji Wang
- Feifei Chen
- Kaisu Lin
- Mingao Zhu
- Lei Chen
- Xiumin Zhou
- Chong Li
- Hong Zhu
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences (CAS), Beijing 100101, P.R. China
Published online on: May 24, 2016 https://doi.org/10.3892/ijmm.2016.2603
Pages: 275-282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and there is an urgent need to identify effective pharmacological strategies to treat NAFLD. For this purpose, in the present study, we examined the the possible molecular mechanisms responsible for the effects of MgIG and the protective effects of MgIG in a model of NAFLD. The human hepatic L02 cell line and oleic acid were employed to establish an in vitro model of NAFLD. The CCK-8 assay, Hoechst 33258 staining and Annexin V-PI staining were performed in order to evaluate cell viability and apoptosis. Oil red O staining was used to detect lipid accumulation within the L02 cells. We found that MgIG significantly inhibited lipid accumulation and protected the L02 cells against lipid accumulation-induced apoptosis. Key molecules involved in unfolded protein response (UPR) signaling were upregulated in lipid-overloaded hepatic cells whereas MgIG suppressed the activation of the UPR. Furthermore, MgIG significantly inhibited the expression of the downstream inflammatory cytokines which had been induced by lipid accumulation. Taken together, these findings suggest that the activation of UPR signaling induces the expression of inflammatory cytokines through the activation of nuclear factor-κB (NF-κB) in lipid-overloaded hepatic cells. In addition, MgIG may suppress the activation of UPR signaling thereby protecting hepatic cells from NAFLD‑induced injury.

View Figures

View References

1	Angulo P and Lindor KD: Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 17(Suppl): S186–S190. 2002. View Article : Google Scholar : PubMed/NCBI
2	Başaranoğlu M and Örmeci N: Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. Turk J Gastroenterol. 25:127–132. 2014. View Article : Google Scholar
3	Du J, Ma YY, Yu CH and Li YM: Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 20:569–577. 2014. View Article : Google Scholar : PubMed/NCBI
4	Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L and Velagić V: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 13:4539–4550. 2007. View Article : Google Scholar : PubMed/NCBI
5	Takahashi Y, Sugimoto K, Inui H and Fukusato T: Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 21:3777–3785. 2015. View Article : Google Scholar : PubMed/NCBI
6	Papandreou D and Andreou E: Role of diet on non-alcoholic fatty liver disease: an updated narrative review. World J Hepatol. 7:575–582. 2015. View Article : Google Scholar : PubMed/NCBI
7	Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM and Sanyal AJ: Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 134:568–576. 2008. View Article : Google Scholar
8	Zhang K and Kaufman RJ: The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology. 66(Suppl 1): S102–S109. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kim SR, Kim DI, Kang MR, Lee KS, Park SY, Jeong JS and Lee YC: Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation. J Allergy Clin Immunol. 132:1397–1408. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ayala P, Montenegro J, Vivar R, Letelier A, Urroz PA, Copaja M, Pivet D, Humeres C, Troncoso R, Vicencio JM, et al: Attenuation of endoplasmic reticulum stress using the chemical chaperone 4-phenylbutyric acid prevents cardiac fibrosis induced by isoproterenol. Exp Mol Pathol. 92:97–104. 2012. View Article : Google Scholar
11	Hotamisligil GS: Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 140:900–917. 2010. View Article : Google Scholar : PubMed/NCBI
12	Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J and Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 11:183–190. 2005. View Article : Google Scholar : PubMed/NCBI
13	Li N and Karin M: Signaling pathways leading to nuclear factor-kappa B activation. Methods Enzymol. 319:273–279. 2000. View Article : Google Scholar : PubMed/NCBI
14	Bao QD, Yang LL and Wang L: Protective effects of magnesium isoglycyrrhizinate against carbon tetrachloride-induced acute liver injury in mice. World Chin J Digestology. 16:1004–1007. 2008.
15	Dong LP, Yu F, Liu J and Mu XM: Protective effect of magnesium isoglycyrrhizinate on acute hepatic injury in mice. China Pharmacy. 17:902–904. 2006.
16	Mao YM, Zeng MD, Chen Y, Chen CW, Fu QC, Cai X, Wu SM, Chen YG, Sun Y, Li J, et al: Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study. Zhonghua Gan Zang Bing Za Zhi. 17:847–851. 2009.In Chinese. PubMed/NCBI
17	Cheng Y, Zhang J, Shang J and Zhang L: Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro. Pharmacology. 84:183–190. 2009. View Article : Google Scholar : PubMed/NCBI
18	Xiao ZW, Zhang W, Ma L and Qiu ZW: Therapeutic effect of magnesium isoglycyrrhizinate in rats on lung injury induced by paraquat poisoning. Eur Rev Med Pharmacol Sci. 18:311–320. 2014.PubMed/NCBI
19	Chen KJ, Chen WY, Chen X, Jia YM, Peng GQ and Chen L: Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. Eur J Drug Metab Pharmacokinet. 39:25–31. 2014. View Article : Google Scholar
20	Abe K, Ikeda T, Wake K, Sato T, Sato T and Inoue H: Glycyrrhizin prevents of lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol. 60:91–97. 2008. View Article : Google Scholar : PubMed/NCBI
21	Ziamajidi N, Khaghani S, Hassanzadeh G, Vardasbi S, Ahmadian S, Nowrouzi A, Ghaffari SM and Abdirad A: Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food Chem Toxicol. 58:198–209. 2013. View Article : Google Scholar : PubMed/NCBI
22	Alkhatatbeh MJ, Lincz LF and Thorne RF: Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease. Exp Ther Med. 11:1487–1492. 2016.PubMed/NCBI
23	Malhi H, Bronk SF, Werneburg NW and Gores GJ: Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem. 281:12093–12101. 2006. View Article : Google Scholar : PubMed/NCBI
24	Henkel A and Green RM: The unfolded protein response in fatty liver disease. Semin Liver Dis. 33:321–329. 2013. View Article : Google Scholar : PubMed/NCBI
25	Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP and Ron D: CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 18:3066–3077. 2004. View Article : Google Scholar : PubMed/NCBI
26	Yoshida H, Matsui T, Yamamoto A, Okada T and Mori K: XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 107:881–891. 2001. View Article : Google Scholar
27	Adachi Y, Yamamoto K, Okada T, Yoshida H, Harada A and Mori K: ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic reticulum. Cell Struct Funct. 33:75–89. 2008. View Article : Google Scholar : PubMed/NCBI
28	Cao J, Dai DL, Yao L, Yu HH, Ning B, Zhang Q, Chen J, Cheng WH, Shen W and Yang ZX: Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway. Mol Cell Biochem. 364:115–129. 2012. View Article : Google Scholar : PubMed/NCBI
29	Deng J, Lu PD, Zhang Y, Scheuner D, Kaufman RJ, Sonenberg N, Harding HP and Ron D: Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol. 24:10161–10168. 2004. View Article : Google Scholar : PubMed/NCBI
30	Hu P, Han Z, Couvillon AD, Kaufman RJ and Exton JH: Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol Cell Biol. 26:3071–3084. 2006. View Article : Google Scholar : PubMed/NCBI
31	Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP and Ron D: Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 287:664–666. 2000. View Article : Google Scholar : PubMed/NCBI
32	Nerstedt A, Cansby E, Amrutkar M, Smith U and Mahlapuu M: Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes. Mol Cell Endocrinol. 375:68–78. 2013. View Article : Google Scholar : PubMed/NCBI
33	Dooley S and ten Dijke P: TGF-β in progression of liver disease. Cell Tissue Res. 347:245–256. 2012. View Article : Google Scholar
34	Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R and Seki E: TGF-β signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism. Hepatology. 59:483–495. 2014. View Article : Google Scholar
35	Henderson NC and Iredale JP: Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond). 112:265–280. 2007. View Article : Google Scholar
36	Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G and Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 107:450–455. 1999. View Article : Google Scholar : PubMed/NCBI